Estimation of proarrhythmic hazards by QT prolongation/shortening: QT obsession?

Drug Information Journal

Volumn 40, Issue 3, 2006, Pages 273-279

  Hondeghem, Luc M ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE   (Belgium)

Author keywords

Proarrhythmia; QT prolongation; QT shortening; Torsade de points; Ventricular fibrillation

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ANTIARRHYTHMIC ACTIVITY; DISEASE ASSOCIATION; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; TORSADE DES POINTES;

EID: 33747619197     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150604000306     Document Type: Review

References (21)

1. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol. 1970;39:675-687.
2. Vaughan Williams EM. Classification of antiarrhythmic agents. In Vaughan Williams EM, ed. Antiarrhythmic Drugs. Berlin: Springer-Verlag; 1989:45-67. Handbook of Experimental Pharmacology Series; No. 89.
3. Fenichel RR, Malik M, Antzelevitch C, et al. J Cardiovasc Electr. 2001;15:475-495
4. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use-dependence. Circulation. 1990;81:686-690.
5. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7-12.
6. Hondeghem L, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythrnia, but APD prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013.
7. Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods. 2004;49:171-181
8. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2005;2:758-772.
9. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation. 2004;110:2453-2459.
10. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24:619-625.
11. Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol. 2003;41:14-24.
12. Hondeghem LM, Lu HR, van Rossem K, De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol. 2003;14:287-294.
13. Antzelevitch C, Shimizu W, Yan GX, Sicouri S. Cellular basis for QT dispersion. J Electrocardiol. 1998;30:168-175.
14. Lu HR, Vlaminckx E, Van Ammel K, De Clerck F. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. Eur J Pharmacol. 2002;452:183-192.
15. Sugiyama A. Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models. Nippon Yakurigaku Zasshi. 2003;121:393-400.
16. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218-225.
17. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther. 2002;300:64-71.
18. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
19. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol. 2004;43:369-379.
20. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363-1372.
21. Hondeghem LM. TRIaD: foundation for proarrhythmia (triangulation, reverse use dependence, and instability). In The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome. Novartis Foundation Symposium 266. New York: Wiley; 2005:235-250.